novo nordisk's semaglutide failed to slow alzheimer's disease progression Blockbuster GLP-1 Diabetes and Weight Loss Drugs Fails in Alzheimer's Trial

GLP-1 Semaglutide Fails to Slow Alzheimer's Despite Biomarker Changes

22.05

★★★★☆4.8 (126)

The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. Read more at: https://www.medpagetoday.com/neurology/alzheimersdisease

21.03

★★★★★4.9 (98)

Two of the most anticipated studies this year—large-scale, randomized, controlled, and double-blinded trials of the popular obesity and diabetes drug semaglutide for Alzheimer's disease—have unfortunately ended in a dud. An oral version

21.77

★★★★★5.0 (157)

Novo Nordisk Shares Fall 12% After Ozempic Pill Fails in Alzheimer's Effort

26.71

★★★★★4.7 (84)

Novo's semaglutide gamble in Alzheimer's draws a blank

23.69

★★★★★4.9 (203)

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

29.78

★★★★★5.0 (176)

Two of the most anticipated studies this year—large-scale, randomized, controlled, and double-blinded trials of the popular obesity and diabetes drug semaglutide for Alzheimer's disease—have unfortunately ended in a dud. An oral version

29.06

★★★★★4.8 (132)